331 related articles for article (PubMed ID: 34093863)
21. TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma.
Damo M; Wilson DS; Simeoni E; Hubbell JA
Sci Rep; 2015 Dec; 5():17622. PubMed ID: 26631690
[TBL] [Abstract][Full Text] [Related]
22. Amplified Cancer Immunotherapy of a Surface-Engineered Antigenic Microparticle Vaccine by Synergistically Modulating Tumor Microenvironment.
Zhao H; Zhao B; Wu L; Xiao H; Ding K; Zheng C; Song Q; Sun L; Wang L; Zhang Z
ACS Nano; 2019 Nov; 13(11):12553-12566. PubMed ID: 31689085
[TBL] [Abstract][Full Text] [Related]
23. Empowering dendritic cell cancer vaccination: the role of combinatorial strategies.
Galati D; Zanotta S
Cytotherapy; 2018 Nov; 20(11):1309-1323. PubMed ID: 30360963
[TBL] [Abstract][Full Text] [Related]
24. Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2.
Li M; Shi H; Mu Y; Luo Z; Zhang H; Wan Y; Zhang D; Lu L; Men K; Tian Y; Wu X; Liu X; Pan Y; Fan Y; Yu C; Zhou B; Xiang R; Chen X; Yang L
Mol Cancer; 2014 Jul; 13():179. PubMed ID: 25070035
[TBL] [Abstract][Full Text] [Related]
25. Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response.
Garris CS; Luke JJ
Clin Cancer Res; 2020 Aug; 26(15):3901-3907. PubMed ID: 32332013
[TBL] [Abstract][Full Text] [Related]
26. Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel.
Dai X; Meng J; Deng S; Zhang L; Wan C; Lu L; Huang J; Hu Y; Zhang Z; Li Y; Lovell JF; Wu G; Yang K; Jin H
Theranostics; 2020; 10(7):3049-3063. PubMed ID: 32194854
[TBL] [Abstract][Full Text] [Related]
27. Targeting Innate Immunity to Enhance the Efficacy of Radiation Therapy.
Dar TB; Henson RM; Shiao SL
Front Immunol; 2018; 9():3077. PubMed ID: 30692991
[TBL] [Abstract][Full Text] [Related]
28. Supramolecular assembly of a trivalent peptide hydrogel vaccine for cancer immunotherapy.
Song H; Su Q; Nie Y; Zhang C; Huang P; Shi S; Liu Q; Wang W
Acta Biomater; 2023 Mar; 158():535-546. PubMed ID: 36632876
[TBL] [Abstract][Full Text] [Related]
29. In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy.
Han HD; Byeon Y; Jang JH; Jeon HN; Kim GH; Kim MG; Pack CG; Kang TH; Jung ID; Lim YT; Lee YJ; Lee JW; Shin BC; Ahn HJ; Sood AK; Park YM
Sci Rep; 2016 Dec; 6():38348. PubMed ID: 27910914
[TBL] [Abstract][Full Text] [Related]
30. Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming.
Steele L; Errington F; Prestwich R; Ilett E; Harrington K; Pandha H; Coffey M; Selby P; Vile R; Melcher A
Mol Cancer; 2011 Feb; 10():20. PubMed ID: 21338484
[TBL] [Abstract][Full Text] [Related]
31. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
[TBL] [Abstract][Full Text] [Related]
32. Degradation-regulated architecture of injectable smart hydrogels enhances humoral immune response and potentiates antitumor activity in human lung carcinoma.
Duong HTT; Thambi T; Yin Y; Kim SH; Nguyen TL; Phan VHG; Kim J; Jeong JH; Lee DS
Biomaterials; 2020 Feb; 230():119599. PubMed ID: 31718883
[TBL] [Abstract][Full Text] [Related]
33. Chitosan hydrogel vaccine generates protective CD8 T cell memory against mouse melanoma.
Highton AJ; Kojarunchitt T; Girardin A; Hook S; Kemp RA
Immunol Cell Biol; 2015 Aug; 93(7):634-40. PubMed ID: 25708538
[TBL] [Abstract][Full Text] [Related]
34. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.
Moynihan KD; Opel CF; Szeto GL; Tzeng A; Zhu EF; Engreitz JM; Williams RT; Rakhra K; Zhang MH; Rothschilds AM; Kumari S; Kelly RL; Kwan BH; Abraham W; Hu K; Mehta NK; Kauke MJ; Suh H; Cochran JR; Lauffenburger DA; Wittrup KD; Irvine DJ
Nat Med; 2016 Dec; 22(12):1402-1410. PubMed ID: 27775706
[TBL] [Abstract][Full Text] [Related]
35. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.
Duewell P; Kisser U; Heckelsmiller K; Hoves S; Stoitzner P; Koernig S; Morelli AB; Clausen BE; Dauer M; Eigler A; Anz D; Bourquin C; Maraskovsky E; Endres S; Schnurr M
J Immunol; 2011 Jul; 187(1):55-63. PubMed ID: 21613613
[TBL] [Abstract][Full Text] [Related]
36. Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.
Wang HY; Wang RF
Adv Immunol; 2012; 114():151-76. PubMed ID: 22449781
[TBL] [Abstract][Full Text] [Related]
37. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.
Prins RM; Craft N; Bruhn KW; Khan-Farooqi H; Koya RC; Stripecke R; Miller JF; Liau LM
J Immunol; 2006 Jan; 176(1):157-64. PubMed ID: 16365406
[TBL] [Abstract][Full Text] [Related]
38. Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.
Bose A; Lowe DB; Rao A; Storkus WJ
Melanoma Res; 2012 Jun; 22(3):236-43. PubMed ID: 22504156
[TBL] [Abstract][Full Text] [Related]
39. Lipo-Based Vaccines as an Approach to Target Dendritic Cells for Induction of T- and iNKT Cell Responses.
Stolk DA; de Haas A; Vree J; Duinkerken S; Lübbers J; van de Ven R; Ambrosini M; Kalay H; Bruijns S; van der Vliet HJ; de Gruijl TD; van Kooyk Y
Front Immunol; 2020; 11():990. PubMed ID: 32536918
[TBL] [Abstract][Full Text] [Related]
40. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
